SPECULATION STOCKS

[kiy]

DVAX...Dynavax is nearing a pivotal advisory committee meeting for its experimental hepatitis B vaccine, Heplisav-B, on July 28, 2017. To be honest, this upcoming regulatory catalyst is likely to play a much larger role in the company's near-term valuation than SD-101's early-stage results. So, before buying shares, investors should feel comfortable with Heplisav-B's chances heading into its advisory committee meeting next month. (Fool.com) Some say this stock can double from here...
Looks priced in to me...so a put call spread spread might be a play...
60minute

Daily



DVAX Dynavax hepatitis B vaccine, skin cancer